soul trial oral semaglutide cardiovascular outcomes 2024 2025 results SOUL: Cuts CV Events in Diabetic Patients Oral Semaglutide and Cardiovascular Outcomes

Summary: Retatrutide is an unlicensed investigational medicine in the UK, and no MHRA-approved reconstitution calculator or protocol exists for patient use

Post-marketing pharmacovigilance data similarly have not established a causal link between semaglutide use and MTC in humans, though ongoing monitoring continues

Effects on Hormone Pathways Beyond local repair, BPC 157 appears to interact with the nitric oxide system, affecting blood flow regulation and immune signaling

Consistently, hepatic expression of LXR target genes, such as Fasn , Scd1 and Acaca , positively correlates with liver steatosis and liver TG in MASLD mouse models, whereas Srebf1 expression positively correlates with plasma TG 40 (Extended Data Fig